. Author manuscript; available in PMC: 2021 Nov 19.

Published in final edited form as: J Pharm Pharm Sci. 2021;24:267–276. doi: 10.18433/jpps31832

Table 1.

Pharmacokinetic parameters for α-PVP after 0.56, 1, and 3 mg/kg sc administration of α-PVP in control and vaccinated rats reported as mean ± SD.

Dose (mg/kg)	Treatment (N)	Half-life (h)	C_max (ng/mL)	AUC_inf (n•min/mL)	CL/F (mL/min/kg)	Vd/F (L/kg)
0.56	Control (6)	1.97 ± 0.97	75 ± 24	7943 ± 1791	73 ± 14	14.1 ± 4.7
	Vaccine (6)	1.35 ± 0.23^*	557 ± 273^*	75932 ±37671^*	9 ± 5^*	1.1 ± 5.1^*

1.0	Control (6)	2.54 ± 0.58	135 ± 37	13634 ± 3327	77 ±17	17.9 ± 5.9
	Vaccine (6)	1.33 ± 0.26^*	646 ± 181^*	100958 ±40732^*	11 ± 5^*	1.3 ± 0.3^*

3.0	Control (6)	1.82 ± 0.36	291 ± 71	32712 ± 4501	94 ± 15	15.6 ± 4.0
	Vaccine (6)	1.77 ± 0.55	1117 ± 354^*	208402 ±98795^*	18 ± 12^*	2.7 ± 1.0^*

Asterisks indicate significant difference from the control rats at the same α-PVP dose (*p<0.05).